ERBB2 and pancreatic neoplasm: Beside the report by Yamanaka et al, there are two reports by Safran et al (2001, 2004) who first screened 154 patients with pancreatic cancer and showed HER2 overexpression in 21% (Safran et al, 2001) and 16% (Safran et al, 2004) of patients, respectively.